Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RuiYi
La Jolla, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
RuiYi is a biotechnology company focused on the discovery and development of novel therapeutic monoclonal antibodies targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary iMAb platform to identify and optimize functional antibodies against traditionally difficult-to-target GPCRs. Its lead asset, gerilimzumab (RYI-008), is a highly potent anti-IL-6 monoclonal antibody developed for the treatment of rheumatoid arthritis and other inflammatory conditions. RuiYi operates with a dual-hub model, maintaining research and development facilities in both La Jolla, California, and Shanghai, China. The company was acquired by Araxes Pharma in 2016 to further advance its pipeline of GPCR-targeted biologics.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodyAntibodyBiologic
- Industry
- Biotech
02
Partnerships
GenclorArgenx
Beyond the preview
Go deeper on RuiYi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RuiYi.